U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07228078) titled 'Open-Label Extension Protocol to SNK01-AD01 Study' on Nov. 12.
Brief Summary: Open-Label Extension Protocol to SNK01-AD01 Study
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Intervention:
BIOLOGICAL: SNK01
SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
Recruitment Status: RECRUITING
Sponsor: NKGen Biotech, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....